KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Current Deferred Revenue (2016 - 2017)

Pacira BioSciences has reported Current Deferred Revenue over the past 8 years, most recently at $102000.0 for Q4 2017.

  • For Q4 2017, Current Deferred Revenue fell 82.86% year-over-year to $102000.0; the TTM value through Dec 2017 reached $102000.0, down 82.86%, while the annual FY2017 figure was $102000.0, 82.86% down from the prior year.
  • Current Deferred Revenue for Q4 2017 was $102000.0 at Pacira BioSciences, down from $520000.0 in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $1.4 million in Q2 2014 and troughed at $102000.0 in Q4 2017.
  • A 5-year average of $1.1 million and a median of $1.0 million in 2013 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 86.56% in 2013 and later soared 46.71% in 2014.
  • Year by year, Current Deferred Revenue stood at $1.0 million in 2013, then surged by 41.47% to $1.4 million in 2014, then changed by 0.0% to $1.4 million in 2015, then plummeted by 58.27% to $595000.0 in 2016, then crashed by 82.86% to $102000.0 in 2017.
  • Business Quant data shows Current Deferred Revenue for PCRX at $102000.0 in Q4 2017, $520000.0 in Q1 2017, and $595000.0 in Q4 2016.